Research & Innovation 2021

Paul Finn

No Image
Paul Finn
Oxford Drug Design

Presentations at Research & Innovation 2021

Wed24  Feb03:10pm(15 mins)
Machine Learning Guided Design of Novel Mode of Action Gram-negative Antibiotics

Session: Innovative medicines: novel antimicrobials and microbiome interventions
Room: Conference Hall Track 2

Profile of Paul Finn

Paul completed his undergraduate biochemistry degree at St Peter’s College, Oxford in 1981 and holds a PhD from Manchester University (1985) on the prediction of protein structure by theoretical methods.
Moving to industry, Paul worked as a scientist in the computational chemistry group at SmithKline Beecham, and then Pfizer. In 1998 Paul switched to biotech, joining Prolifix, subsequently acquired by TopoTarget, which focused on oncology. As Director of R&D Paul was responsible for TopoTarget’s extremely successful HDAC inhibitor programme which led to the discovery and development of belinostat, which was approved by the FDA for the treatment of Peripheral T-cell Lymphoma in 2014.
In 2004 Paul moved to InhibOx, now Oxford Drug Design, a spin-out company from the Chemistry Department of the University of Oxford, where he is CSO. Oxford Drug Design is a biotechnology company advancing a pipeline of drug candidates for the treatment of drug-resistant bacterial infections.
Please login to send a Private Message

Hosted By
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App
Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG, eventflo, Labhoo Ltd 2003-2020